A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

Inclusion Criteria: * Male or surgically sterile female of non-childbearing potential (post-menopausal, ie natural or induced menopause with last menstruation \>1 year ago and LH and FSH in the post-menopausal range, and/or have undergone hysterectomy and/or bilateral oophorectomy * Diagnosed diabetes Mellitus patients treated with diet and exercise alone or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment * HbA1c ≤10.5 % at screening (HbA1c value according to international DCCT standard) Exclusion Criteria: * Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP * History ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease * Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results. Positive test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to Hepatitis C virus